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Genetic Aspects of Hepatocellular Carcinogenesis 
MEHMET OZTURK, Ph.D 
ABSTRACT: Hepatocellular carcinoma (HCC) is linked etiologically to viruses (hepatitis B virus [HBV] and hep- 
atitis C virus [HCV]),  chemical carcinogens (i.e., aflatoxins), and other environmental and host ,factors causing 
chronic liver injury. Some hepatoblastomas may be linked to inherited gene mutations, but adult hereditary HCC up- 
pears to be rare. HCCs display gross genomic ultel-ations, including DNA rearrangements associated with HBV 
DNA integration, loss cf heterozygosity, and, less importantly, chromosomal amplifications and loss of imprinting. 
Many genes with somatic mutations have now been identified in these tumors. Most frequently involved genes are tu- 
mor suppressor genes such as p53, M6P/IGF2R, p-catenin, p16INK4A, and retinoblastoma genes. Most identified 
mutations are somatic, but germline mutations of pl61NK4A, APC, and BRCA2 have also been reported. Oncogenic 
activation of several cellular genes such as cyclin D and cyclin A have been described in HCC, but the possible im- 
plication of candidate viral oncogenes (i.e., X protein of HBV) is still debuted. A comprehensive analysis of all the 
genetic changes described for HCC demonstrates that at least four different growth regulatory pathways are altered 
in these tumors. However, each pathway appears to be implicated in a limited fraction of these tumors, suggesting 
that HCCs are genetically heterogenous neoplasms. This genetic heterogeneity correlates with the heterogeneity qf 
etiologic factors implicated in HCC. 
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Hepatocellular carcinoma (HCC) cells often display 
chromosomal changes such as polyploidy, loss of het- 
erozygosity (LOH), allelic imbalance (AI), amplifica- 
tions, and trans1ocations.l It has also been known for a 
long time that hepatitis B virus (HBV) DNA causes chro- 
mosomal rearrangements by integration into the host 
genome.? It is expected that the chromosomal regions 
that undergo tumor-specific changes harbor critical genes 
involved directly (oncogenes and tumors suppressor 
genes) or indirectly (DNA repair genes) in carcinogene- 
sis. To date, a dozen genes, including p53, mannose-6- 
phosphate/insulin-like factor 2 receptor (M6P/ IGF2R), 
p-catenin, retinoblastoma (RBI ) ,  p161NK4A, adeno- 
matosis polyposis coli (APC),  breast cancer gene 2 
(BRCAZ), cyclin A, cyclin D, and insulin-like growth 
factor 2 (IGF2) have been shown to be altered in HCC 
and/or hepatoblastoma (Table 1). This list will probably 
grow over the next years to include many more genes. 
There are at least two reasons to explain the high num- 
ber of altered genes in HCC. First, solid tumors of the 
adult may need the accumulation of many genetic alter- 
ations before they become clinically detectable. Indeed, 
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TABLE 1. Genetic Alterations in 
Hepatocellular Carcinoma and Hepatoblastoma 
Gene Mutation (%) Other Alterations References 
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*Somatic and germline mutations. 
+Amplification. 
*In hepatoblastoma only. 
HD, homozygous deletion. 
LOH, loss of heterozygosity. 
LOI, loss of imprinting. 
the well-known "latent period" between the first expo- 
sure to an etiologic agent (i.e., infection with HBV) and 
the development of HCC is in favor of such a hypothe- 
sis.3 Second, the multiplicity of genetic alterations in 
HCC may indicate that different etiologic factors affect 
different sets of target genes in hepatocytes. This etio- 
logically defined genetic heterogeneity of HCC results 
in a phenotypic heterogeneity of these tumors. In other 
words, distinct but related growth regulatory pathways 
are altered during hepatocarcinogenesis. As discussed 
later, at least four different pathways are altered in hu- 
man HCCs. 
p53 GENE 
Many reports now indicate that the p53 gene, which 
is located on chromosome 17p, is mutated in about 30% 
of HCCs worldwide (for a recent review, see ref. 4). All 
reported p53 mutations in HCC are somatic. Therefore, 
germline mutations of p53 appear not to predispose to 
HCC. Both the frequency and the type of p53 mutations 
are different depending on geographic location and sus- 
pected etiology of these tumors (Table 2). An HCC- 
specific codon 249 mutation (AGG -+ AGT) leading to 
an arginine to serine substitution (R249S), suspected to 
be induced by aflatoxins, was found in most HCCs from 
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high risk of exposure to aflatoxins.5-7 This mutation was 
found in 50% of HCCs from Mozambique,8,9 50 to 75% 
of HCCs from Qidong province of China,6.10J1 and 67% 
of HCCs from Senegal.7 A worldwide study by Ozturk 
et a1.8 suggested a close correlation between the pres- 
ence of codon 249 mutations in HCC and high risk of 
aflatoxin intake. This early study has now been largely 
confirmed by others. As shown in Table 1, the codon 
249 mutation is present in 36% of tumors from Africa 
and 32% of tumors from China, respectively. These two 
regions of the world are known for high incidence of 
HCC, where both HBV and aflatoxins are recognized as 
major etiologic factors. In contrast, the codon 249 muta- 
tion is seen in less than 4% of HCCs from Japan, Eu- 
rope, and North America, where HBV and hepatitis C 
virus (HCV), but not aflatoxins, are the main etiologic 
factors. The overall frequency of codon 249 mutations 
in the world is 11 %. Mutations affecting other codons of 
the p53 gene are detected in HCC, and their worldwide 
frequency is 18%. The frequency of all p53 mutations in 
HCC varies between 15% in Europe and 42% in China, 
with a worldwide frequency of 27% (see Table 2 for a 
detailed analysis of p53 mutations). Thus, p53 gene is 
mutated in about a third of HCCs, but only a third of 
these mutations can be etiologically linked to a high risk 
of aflatoxin exposure. Therefore, p53 mutations can oc- 
cur in HCC independent of aflatoxin risk, and in HBV 
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TABLE 2. Frequency of p53 Mutations 
in Hepatocellular Carcinoma 









Data were compiled from references 6, 7, 9-1 1, 45, 64-89, 98 and 102-104. The numbers do 
not add up for two reasons: in some studies only the p53-249 mutation was reported; in some 
others only the information of the total number of mutations was reported. 
"U.S.A. including Alaska. 
+Mexico only. 
*South Africa, Mozambique, and Senegal only. 
+Mainland China and Hong Kong. 
IAustralia, Singapore, South Korea, Taiwan, Thailand. 
apparent association between the presence of X gene 
coding sequences of HBV (HBx) and wild-type p53 in 
HCC. Based on this observation, a possible interference 
of HBV with wild-typep53 function was suggested.Vn- 
deed, recent studies showed that HBx protein encoded 
by the X region of HBV interacts with wild-type p53 
protein both physically and functionally.l2-15 These ob- 
servations suggest that the suspected oncogenic activity 
of HBx protein is linked to functional inactivation of 
wild-type p53 protein, as observed with other viral pro- 
teins with transforming activity. However, the interac- 
tion of HBx with p53 was shown only experimentally. It 
is presently unclear whether HBx-p53 interactions 
really occur in HBV-infected hepatocytes and/or in 
HCC cells with integrated HBV DNA sequences. 
Frequent involvement of p53 mutations in HCC is 
not surprising for several reasons. First, the p53 gene is 
the only known gene to be mutated at a very high fre- 
quency in tumors of different origin.16 Second, this pro- 
tein is involved in different cellular processes (cell cy- 
cle arrest, apoptosis, differentiation, angiogenesis, etc.), 
all critically involved in the development of malig- 
nancy.[' Under physiologic conditions, p53 protein is 
complexed with MDM2 protein that promotes a rapid 
degradation of p53. MDM2-p53 complexes are inhib- 
ited either by pl9ARF (induced by both cellular and vi- 
ral oncogenes) or by N-terminal phosphorylation of p.53 
by DNA-dependent protein kinase. This leads to an ac- 
cumulation and functional activation of p53 in cells, 
leading to either cell cycle arrest by p21 or apoptosis by 
bax induction. Thus, p53 protein appears to be involved 
in a growth control response to abnormal oncogene ex- 
pression and DNA damage.17 In patients with chronic 
liver disease, the risks of oncogene activation and DNA 
damage are elevated. As stated earlier, HBx may have 
an oncogenic activity and aflatoxins are potent DNA 
damaging agents. 
p16/NK4A, CYCLIN D, AND 
RETINOBLASTOMA GENES 
These three genes encode for proteins involved in 
the regulation of the GI phase of the cell cycle. Cyclin D 
forms active complexes with CDK4 protein, whereas 
p16 protein is an inhibitor of CDK4 activity.18 The 
retinoblastoma protein (pRb) is the main known sub- 
strate of CDK4. In nonproliferating cells, pRb protein 
forms complexes with E2F transcription factors. When 
complexed to pRb, E2Fs are transcriptionally inactive. 
Upon phosphorylation by CDK4, pRb is released from 
its complexes and "free E2Fs" promote the initiation of 
DNA synthesis.lYhese observations predict that the 
loss of pRb protein or its aberrant phosphorylation will 
lead to a loss of growth control at the GI phase of the 
cell cycle. Increased phosphorylation of pRb may result 
from an aberrant activation of CDK4 by either an excess 
of cyclin D and/or a deficit in p16 protein. Recent stud- 
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p161NK4A, and cyclin D, undergo structural alterations 
in HCC. The retinoblastoma gene (RBI) is one of the tu- 
mor suppressor genes studied in HCC just after the im- 
plication of p53 in these tumors. LOH at the RBI gene 
locus is quite frequent in HCC. In addition, RBI muta- 
tions were observed in 15% of these tumors (Table 1 ). 
The p161NK4A gene, which is located at chromo- 
some 9p, codes for two alternatively spliced tran- 
scripts.l7.18 One of the transcripts is for p16 protein, 
an inhibitor of cyclin-dependent kinases 4 and 6.Ix 
p161NK4A status in HCC has been studied indepen- 
dently by several laboratories. Both germline and so- 
matic mutations of pl6INKA were found in HCC pa- 
tients. It was also reported that about 50% of HCC 
display de novo methylation of p161NK4A, as observed 
in other cancers (see Table 1 and references therein). It 
is known that de novo methylation is a mechanism in- 
volved in gene silencing.") Therefore, one can assume 
that HCC cells with methylatedp16INK4A are unable to 
express the gene, leading to the loss of a cyclin-depen- 
dent kinase inhibitor protein. 
As shown in Table 1, cyclin D and cyclin A genes 
were shown to be amplified in 10-20% of HCCs. It is 
noteworthy that RBI, pI6INKA, and cyclin genes are 
mutated individually in 10 to 20% of HCCs. Although 
this frequency is not high, their involvement in the same 
growth regulatory pathway implies that when com- 
bined, these mutations will lead a loss of growth control 
in more than 30% of HCCs. 
M6PlIGF2 RECEPTOR, SMAD2, 
AND SMAD4 GENES 
The mannose-6-phosphate/insulin-like growth fac- 
tor 2 receptor (M6PIIGF2R) is involved in the activation 
of transforming growth factor beta (TGF-P), whereas 
SMAD2 and SMAD4 genes are intracellular mediators of 
TGF-P, which induces both growth inhibition and apop- 
totic cell death in hepatocytes.21-2Wfter the demonstra- 
tion of LOH at the M6PIIGF2R gene locus by De Souza 
et al.," several reports described that the MGP/IGF2R 
gene is mutated in 18 to 33% of HCCs (Table 1). 
SMAD2 and SMAD4 genes appear to be mutated in less 
that 10% of these cancers.2452Vn contrast, no mutation of 
TGF-P receptor type I1 was found in HCC.z4 Taken to- 
gether, these observations demonstrate that at least three 
genes involved in TGF-P-mediated growth control are 
altered in HCC and that overall the TGF-P pathway is 
altered in about 25% of HCCs. 
I P53 pathway I 
FIG. 1. Main regulatory pathways altered in human hepatocellular carcinomas. The most frequently mutated genes of each 
pathway are also shown. The vertical arrowed lines connecting four pathways indicate that these pathways are related to each other 
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P-CATENIN, APC, 
AND E-CADHERIN GENES 
The APC gene was initially identified in the famil- 
ial adenomatous polyposis coli syndrome. Germline and 
somatic mutations of APC have been detected in col- 
orectal cancers.26 Some of these cancers display muta- 
tions in the p-catenin gene instead of the APC gene.27 
APC and p-catenin proteins have physical and func- 
tional p-Catenin also forms complexes 
with E-cadherin.29 APC and E-cadherin may be in- 
volved in intercellular interactions.28.29 In contrast, 
p-catenin appears to play a role in transcriptional regu- 
lation in addition to its participation in cell-to-cell inter- 
a c t i o n ~ . ~ ~  Somatic mutations of p-catenin were ob- 
served in 19-26% of HCCs.MO." These mutations that 
occur at the N-terminal region of 6-catenin lead to an 
accumulation of aberrant p-catenin proteins that stimu- 
late the activity of a transcription factor.'8.30,31 Somatic 
APC mutations may be rare in HCC, but they appear to 
be quite frequent in hepatoblastomas.ll.32-" Finally, the 
E-cadherin gene was shown to display frequent LOH 
and de novo methylation in HCC (Table I). Thus, it is 
possible that E-cadherin function is lost in some HCCs. 
Taken together, these observations indicate that the 
"P-cateninlAPC pathway" is altered in more than 30% 
of HCCs. 
OTHER GENETIC ALTERATIONS 
As shown in Table 1, ras and myc oncogenes are not 
frequently mutated in human HCC. Loss of genomic im- 
printing and bi-allelic expression of the IGF2 gene was 
shown in hepatoblastomas and in some HCCs.3g43 
Among other known genes, BRCA2 p21, andp15INK4B 
appear to be involved only rarely in these tumors. MLHl 
and MSH2, two genes involved in DNA mismatch repair, 
have not been studied for possible mutations in HCC 
(Table 1). 
CONCLUDING REMARKS 
Recent studies clearly indicate that many genes un- 
dergo somatic aberrations (point mutations, amplifica- 
tions, loss of imprinting, de novo methylation, etc.) in 
HCC. The number of aberrant genes is high, but the fre- 
quency of individual gene mutations is low. However, 
these mutations are not random. They tend to cluster at 
genes involved in important growth regulatory path- 
ways. Even though the picture is still imperfect, our 
present knowledge of the molecular genetics of HCC 
leads us to four main pathways that are altered in HCC: 
the p53 pathway involved in DNA damage response, the 
RBI pathway involved in cell cycle control, the TGF-fi 
pathway involved in growth inhibition and apoptosis, 
and the P-cateninlAPC pathway involved in morpho- 
genesis and signal transduction. As illustrated in Figure 
1, these pathways should not be considered as indepen- 
dent pathways. They are most probably related to each 
other and may even represent individually a distinct 
step of hepatocellular carcinogenesis. Unfortunately, 
our knowledge of the order of events for the initiation 
and stepwise progression of HCC is still incomplete. 
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hepatitis B virus 
hepatitis C virus 
mannose-6-phosphate/insulin-like 
growth factor I1 receptor 
adenomatosis polyposis coli gene 
gene coding for a 16-kDa inhibitor of 
cyclin-dependent kinase 4 enzyme 
gene coding for a 15-kDa inhibitor of 
cyclin-dependent kinase 4 enzyme 
breast cancer susceptibility gene 2 
X protein of hepatitis B virus 
loss of heterozygosity 
retinoblastoma gene 
protein encoded by the retinblastoma 
gene 
insulin-like growth factor I1 
protein encoded by an alternatively 
spliced form of transcript from 
p161NK4A gene 
human homolog of mouse double mu- 
tant gene 2 
21 -kDa cyclin-dependent kinase in- 
hibitor protein also called CIPl 
cyclin-dependent kinase 4 
a group of transcription factors regu- 
lated by the retinoblastoma family of 
pocket proteins 
transforming growth factor P 
gene encoding a protein involved in 
DNA mismatch repair 
gene encoding for another protein in- 
volved in DNA mismatch repair 
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